TapewireFind a company

person · Reporting owner

Feinberg Peter

Disclosed activity across 2 companies

Tapewire entity
39312
SEC CIK
0001870076

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Immuneering CorpIMRX · Entity 5884DirectorJune 11, 2026June 11, 2026
Notable Labs, Ltd.NTBL · Entity 87239DirectorMay 08, 2024May 10, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Immuneering Corp

Report date June 11, 2026 · Filed June 11, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2036-06-11Direct33,350 Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-11 · Grant · Acquired 33,350 · Balance 33,350

F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

Notable Labs, Ltd.

Report date May 08, 2024 · Filed May 10, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect40,247 Reported balance After 2024-05-08 transaction · row 1
1 source row

Row 1 · 2024-05-08 · Grant · Acquired 40,247 · Balance 40,247

F1: Grant of restricted shares vesting in two equal annual installments from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of restricted shares vesting in two equal annual installments from the date of grant.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 11, 2026 Filed Jun 11, 2026 21:23 UTC Immuneering Corp IMRX · Entity 5884 GrantStock Option · Derivative 33,350 $0.00 Strike: $4.12 $0.00
Disclosure

SEC source: 0001790340-26-000064 · wk-form4_1781213003.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 13:10 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 20,000 $4.35 $86,904.00
Disclosure

SEC source: 0001790340-26-000008 · wk-form4_1768396231.xml · nonDerivative · entry 4

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · General Partner of S4K Investments LLC.

Disclosed balance after: 135,441

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.315 to $4.38. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Read SEC document
January 01, 2026 Filed Jan 2, 2026 21:50 UTC Immuneering Corp IMRX · Entity 5884 GrantStock Option · Derivative 7,888 $0.00 Strike: $6.58 $0.00
Disclosure

SEC source: 0001790340-26-000002 · wk-form4_1767390602.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,888

Underlying: Class A Common Stock · 7,888 shares

Expires 2036-01-01

F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 12:56 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 7,500 $6.67 $50,025.00
Disclosure

SEC source: 0001790340-25-000127 · wk-form4_1759841769.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,766

Read SEC document
September 30, 2025 Filed Oct 1, 2025 12:59 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 7,500 $7.03 $52,730.25
Disclosure

SEC source: 0001790340-25-000119 · wk-form4_1759323577.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,266

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $7.0049 to $7.055. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Read SEC document
September 29, 2025 Filed Sep 30, 2025 13:00 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 5,000 $7.18 $35,900.00
Disclosure

SEC source: 0001790340-25-000117 · wk-form4_1759237255.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,766

Read SEC document
June 18, 2025 Filed Jun 23, 2025 13:09 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 25,000 $2.53 $63,187.50
Disclosure

SEC source: 0001790340-25-000083 · wk-form4_1750684190.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,766

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.07 to $2.96. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Read SEC document
June 13, 2025 Filed Jun 16, 2025 13:04 UTC Immuneering Corp IMRX · Entity 5884 GrantStock Option · Derivative 33,350 $0.00 Strike: $1.90 $0.00
Disclosure

SEC source: 0001790340-25-000069 · wk-form4_1750079056.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2035-06-13

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.

Read SEC document
January 01, 2025 Filed Jan 2, 2025 21:12 UTC Immuneering Corp IMRX · Entity 5884 GrantStock Option · Derivative 23,485 $0.00 Strike: $2.20 $0.00
Disclosure

SEC source: 0001790340-25-000007 · wk-form4_1735852326.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,485

Underlying: Class A Common Stock · 23,485 shares

Expires 2035-01-01

F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.

Read SEC document
June 12, 2024 Filed Jun 13, 2024 20:20 UTC Immuneering Corp IMRX · Entity 5884 GrantStock Option · Derivative 33,350 $0.00 Strike: $1.54 $0.00
Disclosure

SEC source: 0001628280-24-028057 · wk-form4_1718310005.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 12, 2024, and will be fully vested and exercisable on June 12, 2025, or the date of the 2025 annual meeting of stockholders, whichever comes first.

Read SEC document
May 08, 2024 Filed May 10, 2024 21:06 UTC Notable Labs, Ltd. NTBL · Entity 87239 GrantOrdinary Shares 40,247 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-009929 · form4.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,247

F1 · price: Grant of restricted shares vesting in two equal annual installments from the date of grant.

Read SEC document
March 22, 2024 Filed Mar 25, 2024 13:13 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 25,000 $2.55 $63,712.50
Disclosure

SEC source: 0001790340-24-000042 · wk-form4_1711372421.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,766

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.52 to $2.57. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Read SEC document
March 19, 2024 Filed Mar 19, 2024 23:04 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 25,000 $2.56 $64,000.00
Disclosure

SEC source: 0001790340-24-000028 · wk-form4_1710889466.xml · nonDerivative · entry 3

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,766

Read SEC document
March 18, 2024 Filed Mar 19, 2024 23:04 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 4,976 $3.05 $15,201.18
Disclosure

SEC source: 0001790340-24-000028 · wk-form4_1710889466.xml · nonDerivative · entry 2

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,766

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.9863 to $3.1799. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Read SEC document
March 18, 2024 Filed Mar 19, 2024 23:04 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 45,024 $2.31 $103,856.86
Disclosure

SEC source: 0001790340-24-000028 · wk-form4_1710889466.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,790

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.96 to $2.9499. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Read SEC document
January 24, 2024 Filed Jan 26, 2024 16:05 UTC Notable Labs, Ltd. NTBL · Entity 87239 GrantStock Option · Derivative 9,753 $0.00 Strike: $1.28 $0.00
Disclosure

SEC source: 0001062993-24-001366 · form4.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,753

Underlying: Ordinary Shares · 9,753 shares

Expires 2034-01-24

F1 · derivative.exercise_date: Option vests 50% on the first anniversary of date of grant and thereafter in four equal quarterly installments ending on the second anniversary of the date of grant.

Read SEC document
January 01, 2024 Filed Jan 2, 2024 21:26 UTC Immuneering Corp IMRX · Entity 5884 GrantStock Option · Derivative 6,879 $0.00 Strike: $7.35 $0.00
Disclosure

SEC source: 0001790340-24-000002 · wk-form4_1704230750.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,879

Underlying: Class A Common Stock · 6,879 shares

Expires 2034-01-01

F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.

Read SEC document
June 14, 2023 Filed Jun 15, 2023 20:35 UTC Immuneering Corp IMRX · Entity 5884 GrantStock Option · Derivative 17,500 $0.00 Strike: $9.32 $0.00
Disclosure

SEC source: 0001790340-23-000035 · wk-form4_1686861302.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Class A Common Stock · 17,500 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal monthly installments over a one-year period with a vesting commencement date of June 14, 2023, and will be fully vested and exercisable on June 14, 2024, or the date of the 2024 annual meeting of stockholders, whichever comes first.

Read SEC document
June 21, 2022 Filed Jun 23, 2022 21:06 UTC Immuneering Corp IMRX · Entity 5884 GrantStock Option · Derivative 14,200 $0.00 Strike: $4.63 $0.00
Disclosure

SEC source: 0001415889-22-006899 · form4-06232022_020630.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,200

Underlying: Class A Common Stock · 14,200 shares

Expires 2032-06-20

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 21, 2022, and will be fully vested and exercisable on June 21, 2023, or the date of the 2023 annual meeting of stockholders, whichever comes first.

Read SEC document
March 15, 2022 Filed Mar 16, 2022 21:30 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 6,667 $6.75 $45,002.25
Disclosure

SEC source: 0001415889-22-003061 · form4-03162022_020302.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,766

F1 · price: This transaction was executed in multiple trades through a broker-dealer at a price of $6.75. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at such price.

Read SEC document
September 20, 2021 Filed Sep 21, 2021 21:53 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 4,750 $24.45 $116,113.75
Disclosure

SEC source: 0001415889-21-004512 · form4-09212021_020937.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,099

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $23.75 to $24.75. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price.

Read SEC document
September 13, 2021 Filed Sep 15, 2021 21:58 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 349 $21.25 $7,416.25
Disclosure

SEC source: 0001415889-21-004407 · form4-09152021_020922.xml · nonDerivative · entry 2

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349

F2 · price: This transaction was executed in multiple trades through a broker-dealer at a price of $21.25. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price.

Read SEC document
September 13, 2021 Filed Sep 15, 2021 21:58 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 5,750 $21.51 $123,697.45
Disclosure

SEC source: 0001415889-21-004407 · form4-09152021_020922.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · General Partner of PF Associates L.P.

Disclosed balance after: 392,242

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.08 to $22.00. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 ConversionSeries B Preferred Stock · Derivative 30,646 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 12

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 30,646 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F4 · ownership.nature: Mr. Feinberg is a General Partner of S4K Investments LLC.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 ConversionSeries B Preferred Stock · Derivative 30,646 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 11

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 30,646 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F3 · ownership.nature: Mr. Feinberg is a General Partner of PEF LLC.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 ConversionSeries B Preferred Stock · Derivative 30,646 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 10

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 30,646 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F2 · ownership.nature: Mr. Feinberg is a General Partner of PF Associates L.P.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 ConversionSeries A Preferred Stock · Derivative 51,462 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 9

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 51,462 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F4 · ownership.nature: Mr. Feinberg is a General Partner of S4K Investments LLC.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 ConversionSeries A Preferred Stock · Derivative 92,509 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 8

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 92,509 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F3 · ownership.nature: Mr. Feinberg is a General Partner of PEF LLC.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 ConversionSeries A Preferred Stock · Derivative 102,926 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · derivative · entry 7

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 102,926 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F2 · ownership.nature: Mr. Feinberg is a General Partner of PF Associates L.P.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 33,333 $15.00 $499,995.00
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 6

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Foonote

Disclosed balance after: 115,441

F4 · ownership.nature: Mr. Feinberg is a General Partner of S4K Investments LLC.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 ConversionClass A Common Stock 82,108 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 5

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Foonote

Disclosed balance after: 82,108

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F4 · ownership.nature: Mr. Feinberg is a General Partner of S4K Investments LLC.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 129,167 $15.00 $1,937,505.00
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 4

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Foonote

Disclosed balance after: 476,568

F3 · ownership.nature: Mr. Feinberg is a General Partner of PEF LLC.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 ConversionClass A Common Stock 123,155 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 3

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Foonote

Disclosed balance after: 347,401

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F3 · ownership.nature: Mr. Feinberg is a General Partner of PEF LLC.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 PurchaseClass A Common Stock 129,167 $15.00 $1,937,505.00
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 2

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Foonote

Disclosed balance after: 386,492

F2 · ownership.nature: Mr. Feinberg is a General Partner of PF Associates L.P.

Read SEC document
August 03, 2021 Filed Aug 4, 2021 10:06 UTC Immuneering Corp IMRX · Entity 5884 ConversionClass A Common Stock 133,572 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-099742 · tm2123807-9_4seq1.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Foonote

Disclosed balance after: 257,325

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F2 · ownership.nature: Mr. Feinberg is a General Partner of PF Associates L.P.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.